Two ACTive Immunotherapies In Melanoma (TACTI-mel): Results Of A Phase I
Trial With Metastatic Melanoma Patients Treated With A Soluble LAG-3 Receptor
(LAG-3lg Or Eftilagimod Alpha) As An Antigen Presenting (APC) Activator Combined With Pembrolizumab
Fre´de´ric Triebel MD, PhD
Third Annual Advances in Immuno-oncology Congress
London, May 25, 2018
To view Presentation please download PDF attached:
Download this document
